Drug Information
Drug (ID: DG01687) and It's Reported Resistant Information
Name |
Selumetinib/Dactolisib
|
||||
---|---|---|---|---|---|
Synonyms |
Selumetinib/Dactolisib
Click to Show/Hide
|
||||
Target | . | NOUNIPROTAC | [1] |
Type(s) of Resistant Mechanism of This Drug
UAPP: Unusual Activation of Pro-survival Pathway
Drug Resistance Data Categorized by Their Corresponding Diseases
ICD-02: Benign/in-situ/malignant neoplasm
Colorectal cancer [ICD-11: 2B91]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: GTPase KRas (KRAS) | [2] | |||
Molecule Alteration | Missense mutation | p.A146V (c.437C>T) |
||
Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Liver | N.A. | ||
In Vivo Model | Female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunohistochemistry assay | |||
Mechanism Description | The missense mutation p.A146V (c.437C>T) in gene KRAS cause the sensitivity of Selumetinib + Dactolisib by unusual activation of pro-survival pathway | |||
Key Molecule: GTPase KRas (KRAS) | [2] | |||
Molecule Alteration | Missense mutation | p.G12C (c.34G>T) |
||
Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Liver | N.A. | ||
In Vivo Model | Female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunohistochemistry assay | |||
Mechanism Description | The missense mutation p.G12C (c.34G>T) in gene KRAS cause the sensitivity of Selumetinib + Dactolisib by unusual activation of pro-survival pathway | |||
Key Molecule: GTPase KRas (KRAS) | [2] | |||
Molecule Alteration | Missense mutation | p.G12D (c.35G>A) |
||
Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Liver | N.A. | ||
In Vivo Model | Female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunohistochemistry assay | |||
Mechanism Description | The missense mutation p.G12D (c.35G>A) in gene KRAS cause the sensitivity of Selumetinib + Dactolisib by unusual activation of pro-survival pathway | |||
Key Molecule: GTPase KRas (KRAS) | [2] | |||
Molecule Alteration | Missense mutation | p.G12V (c.35G>T) |
||
Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Liver | N.A. | ||
In Vivo Model | Female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunohistochemistry assay | |||
Mechanism Description | The missense mutation p.G12V (c.35G>T) in gene KRAS cause the sensitivity of Selumetinib + Dactolisib by unusual activation of pro-survival pathway | |||
Key Molecule: GTPase Nras (NRAS) | [2] | |||
Molecule Alteration | Missense mutation | p.Q61K (c.181C>A) |
||
Sensitive Disease | Colorectal cancer [ICD-11: 2B91.1] | |||
Experimental Note | Identified from the Human Clinical Data | |||
In Vitro Model | Liver | N.A. | ||
In Vivo Model | Female nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse xenograft model | Mus musculus | ||
Experiment for Molecule Alteration |
Immunohistochemistry assay | |||
Mechanism Description | The missense mutation p.Q61K (c.181C>A) in gene NRAS cause the sensitivity of Selumetinib + Dactolisib by unusual activation of pro-survival pathway |
Melanoma [ICD-11: 2C30]
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms | ||||
Unusual Activation of Pro-survival Pathway (UAPP) | ||||
Key Molecule: Serine/threonine-protein kinase B-raf (BRAF) | [1] | |||
Molecule Alteration | Missense mutation | p.V600E (c.1799T>A) |
||
Sensitive Disease | Melanoma [ICD-11: 2C30.0] | |||
Experimental Note | Revealed Based on the Cell Line Data | |||
In Vitro Model | BRAF-mutant melanoma cells | N.A. | Homo sapiens (Human) | N.A. |
Experiment for Molecule Alteration |
Western blotting analysis | |||
Experiment for Drug Resistance |
MTT assay |
References
If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.